Summary.-The effect of melphalan on the growth of 4 different lines of human lungtumour xenografts has been established. The oat-cell carcinoma was the most sensitive, whereas the adenocarcinoma was the most resistant. Two lines of large-cell anaplastic carcinomas were intermediate in sensitivity. The differences in sensitivity were not reflected in the gross uptake of drug into the tumours. There was, with the exception of the adenocarcinoma line, a marked decrease in uptake per g tumour with increasing tumour size. This was partly caused by a decrease in the vascular supply in the same tumours with increasing tumour size. Extravasation of plasma proteins increased with increasing tumour size in all tumours, but was much less pronounced in the adenocarcinoma than in the other tumour lines. The extracellular volume of the various tumour lines did not vary with tumour size.
ONE OF THE MOST IMPORTANT RESULTS of recent research into the xenografting of human tumours is that it has enabled examples of chemoresistant and chemosensitive tumours to be established in the laboratory, and their sensitivity to treatment to be accurately quantified (Steel, 1978; Shorthouse et al., 1980) . This then enables investigations to be made into the mechanisms underlying sensitivity and resistance. The aim of this study was to examine the relationship between response and drug access in the treatment of 4 different lines of lung-tumour xenografts with the alkylating agent melphalan. The lines were chosen because of their widely different sensitivity to chemotherapeutic agents (Shorthouse et al., 1980) . LD1o of melphalan in tumour-bearing animals was 12 mg/kg. 5mCr-chromium-EDTA, 59Fe-ferric chloride and 1251-human serum albumin were obtained from the Radiochemical Centre, Amersham. Mice. Male CBA/ca/lac mice bred at the Institute of Cancer Research breeding centre, Pollards Wood, were thymectomized at 4 weeks of age and treated with 9 Gy wholebody irradiation from a 60Co source (0.5 Gy/ min) 3-6 weeks later. The lethal effects of this irradiation were prevented by an i.p. injection of Ara-C (200 mg/kg) 2 days before irradiation .
Tumours.-Four types of bronchial carcinomas established as xenograft lines at the Institute of Cancer Research by one of us (A.J.S.) were examined: one oat-cell carcinoma (HX 69), two large-cell anaplastic carcinomas (HX 82 and HX 93) and one adenocarcinoma (HX 70). Tumours were implanted bilaterally as solid 2mm pieces into the flanks of immune-deprived mice.
Growth delay. selected for chemotherapy when their volume was 0-2-0-5 cm3, calculated as 1TDd2/6, where D is the longest diameter of the tumour and d is the diameter perpendicular to D. They were randomly allocated to treatment and control groups, and the therapeutic response was measured by the in situ endpoint of growth delay. A minimum of 5 mice per group was used, giving at least 10 tumours per treatment group. The difference between median time to double in volume of treated and control groups of tumour was determined. Dividing the result by the median doubling time of the control tumours gave an estimate of the number of doubling times saved by each treatment. This parameter allows for comparisons to be made between tumours of different growth rates (Kopper & Steel, 1975) . The loss of body weight during the course of the experiments was minimal.
Drug uptake.-14C-melphalan was dissolved in acid-alcohol (5M HCI: absolute ethanol, 1: 5) and diluted in saline. The dose of melphalan given i.v. was 10-11 mg/kg and the amount of radioactivity per mouse was 0-5-1 0 ,Ci. Four hours later the animals were killed by anaesthetizing with ether, making an incision in the axilla and allowing the animals to bleed freely. This was done to standardize the amount of blood left in the tumours. The tumours were dissected out, put into capsules of combustible polyearbonate and burned in an Intertechnique Oxymat.
In an automatic sequence the 14C-label was trapped in 20 ml of scintillant (330 ml 2-methoxyethylamine, 220 ml methanol, 450 ml toluene and 10 g PPO). The samples were counted in a liquid scintillation counter (Intertechnique). Uptake into muscle was used to correct for possible differences in injected dose and degree of bleeding of the animal when killed. Muscle samples were taken from the quadriceps muscle of both sides and assayed in in parallel with the tumour specimens.
Assessment of residual red-cell volume, plasma volume and extracellular volume of tumours.-The method used is a modification of the method described by Appelgren et al. (1973) . Briefly, 59Fe-labelled erythrocytes were produced by injecting mice with a total of 12 ,uCi of 59Fe-ferric chloride in 0-5% sodium citrate and 0.75% sodium chloride over a period of 2 weeks in 4,Ci doses. Erythrocytes were harvested by bleeding the animals under anaesthesia from the axilla.
Erythrocytes were washed in heparinized saline and then mixed with 1251-labelled human serum albumin and 5ICr chromium-EDTA in saline. A bolus of 0-25 ml containing labelled erythrocytes (equivalent to 0-2 pXCi 59Fe), 2-5 ,uCi 51Cr-EDTA and 1 ,uCi 125J-human serum albumin were injected into the tail veins of tumour-bearing mice. Thirty minutes after injection the recipient animals were killed by bleeding freely under ether anaesthesia. Samples of blood (30 ,A) were taken from the axilla for radioactivity measurement and samples were also taken for the measurement of haematocrit (Hct).
Tumours were dissected out, weighed and counted in an Intertechnique gamma counter for 20 min, again using muscle samples for comparison. The activities in ct/min/ml blood and ct/min/g tissue were calculated. Using the haematocrit values the following parameters were calculated:
RCV: Residual red cell volume (ml)/g of tissue = (5 9Fe activity/g of tissue)/(59Fe activity/ml blood x Hct/100).
PV: Residual plasma volume (ml)/g of tissue = (1 251 activity/g of tissue)/(1 251 activity/ml blood x (1 -Hct/100)).
ECV: Extracellular volume (ml)/g of tissue = (51Cr activity/g of tissue)/(5lCr activity/ml blood x (1 -Hct/100)).
PV measures both intravascular plasma and plasma extravasated during the 30 min. The extravascular plasma volume (EPV) was calculated as: EPV = PV -intravascular plasma volume (IPV); IPV= (RCV x 100/Hct) x (1 -Hct/100). The EPV/IPV ratio is a measure of the extravasation of plasma protein where variations in blood supply and hence the plasma supply are adjusted for.
RESULTS

Growth delay
The effect of melphalan on the growth of the 4 different xenograft lines is shown in Fig. 1 (Table) . This is an uptake as high as that only seen in the small tumours of HX69, 82 and 93 (Fig. 2) .
Residual red cell volume, plasma volume, extracellular volume and vascular permeability The residual red-cell volumes of HX 69, 82 and 93 are shown in Fig. 3 . As with drug uptake there is a striking decrease in RCV with increasing tumour size and the decrease is linearly related to log tumour weight.
The linear regression lines had the following coefficients of correlation: HX 69: Because the blood supply as reflected by RCV decreased with increasing tumour size, the ratio between extra-and intravascular plasma (EPV/IPV) was determined. In all 4 tumours the ratio increased with tumour size, as an indication of increased leakage (Fig. 4) Rutty et al. (1978) comparing the uptake of hexamethylmelamine into P246 bronchial carcinoma xenografts and ADJ/PC6 plasma-cell animal tumours. With the exception of HX 70 the uptake of melphalan into tumours decreased with increasing tumour weight (Fig. 2) . This raised the question of drug access to the various tumours. We therefore examined the vascular supply of the tumours, and looked at parameters such as extracellular volume and extravasation of plasma proteins. With the exception ofthe adenocarcinoma HX 70, the residual red-cell volume decreased with increasing tumour weight (Fig. 3) . The decrease in uptake of melphalan with increasing tumour weight in the oat-cell tumour xenograft and the largecell anaplastic tumour xenografts seems, therefore, at least partly the result of a decreased blood supply. The residual redcell volume of 0-35g oat-cell tumours were only about 4300 that of the adenocarcinoma. This correlates well with the drug uptake in oat-cell tumours being about 550 of that of the adenocarcinoma.
The residtual red-cell volumes of the 4 tumour xeniograft lines are of the same magnitude as those of Song & Levitt (1971) who reported a total blood volume of 7*9 ,ul/g wet weight of rat Walker carcinoma 256.
The extracellular volume seemed not to influence the drug uptake, nor did the extravasation of plasma proteins. The extravasated plasma volume during the 30 min after injection varied between 13-1 and 37-2 pl/g. This is of the same order as that reported for rat Walker carcinoma (Song & Levitt, 1971) In view of the lack of correlation between drug uptake and chemosensitivity, the cause of the reported differences in sensitivity to melphalan in these tumour lines must be sought on the cellular level. Work is in progress investigating drug uptake and chromatin binding in singlecell preparations of these tumours. The development and use of spheroids from tumour cells also open interesting possibilities in studying the mechanisms underlying chemosensitivity and resistance.
An autoradiographic study was attempted, to look at drug distribution within the tumours, but failed because the specific activity of the labelled melphalan was not high enough to yield results with a realistic exposure time.
One of the encouraging findings in this study is the marked growth delay caused by melphalan in oat-cell tumours. The effect was nearly linearly related to drug dose (unpublished observation). This suggests a role of high-dose melphalan in the treatment of oat-cell carcinoma in man.
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